ITP
Iron Triangle Partners Portfolio holdings
AUM
$632M
This Quarter Return
+6.25%
1 Year Return
+26.53%
3 Year Return
+134.07%
5 Year Return
+312.1%
10 Year Return
–
AUM
$632M
AUM Growth
+$632M
(-0.39%)
Cap. Flow
-$39.6M
Cap. Flow
% of AUM
-6.27%
Top 10 Holdings %
Top 10 Hldgs %
60.18%
Holding
37
New
9
Increased
7
Reduced
10
Closed
10
Top Buys
| 1 |
CVS Health
CVS
|
$51.7M |
| 2 |
Charles River Laboratories
CRL
|
$48.6M |
| 3 |
Icon
ICLR
|
$36.4M |
| 4 |
Medtronic
MDT
|
$34.9M |
| 5 |
HCA Healthcare
HCA
|
$30.6M |
Top Sells
| 1 |
DaVita
DVA
|
$48.9M |
| 2 |
Teva Pharmaceuticals
TEVA
|
$34.1M |
| 3 |
Boston Scientific
BSX
|
$33.5M |
| 4 |
Cardinal Health
CAH
|
$32.7M |
| 5 |
Globus Medical
GMED
|
$31.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Insmed
INSM
$30.3B
| $7.04M | 1.08% |
+70,000
| New | +$7.04M |
|
27
Jazz Pharmaceuticals
JAZZ
$7.99B
| – | – |
-130,000
| Closed | -$16.1M |
|
|
28
Globus Medical
GMED
$7.94B
| – | – |
-431,221
| Closed | -$31.6M |
|
|
29
DaVita
DVA
$9.72B
| – | – |
-319,566
| Closed | -$48.9M |
|
|
30
Boston Scientific
BSX
$159B
| – | – |
-332,167
| Closed | -$33.5M |
|
31
AstraZeneca
AZN
$255B
| – | – |
-376,330
| Closed | -$27.7M |
|
32
Agilent Technologies
A
$35.5B
| – | – |
-208,438
| Closed | -$24.4M |
|
33
10x Genomics
TXG
$1.66B
| – | – |
-1,000,000
| Closed | -$8.73M |
|
|
34
Teva Pharmaceuticals
TEVA
$21.5B
| – | – |
-2,217,730
| Closed | -$34.1M |
|
35
Bio-Techne
TECH
$8.3B
| – | – |
-250,000
| Closed | -$14.7M |
|
36
Neurocrine Biosciences
NBIX
$13.5B
| – | – |
-146,836
| Closed | -$16.2M |
|
37
Oscar Health
OSCR
$4.57B
| – | – |
0
| – | – |
|